New hope for advanced cancer: experimental drug SHR-1681 enters human trials

NCT ID NCT06737731

Recruiting now Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called SHR-1681 in 300 people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-1681 (an experimental drug given by injection)
What this could lead to: If it works, this could lead to a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early-phase trial, so the drug may not be effective or could have serious side effects. Success in this small group may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SOLID TUMORS

Contacts and locations

Locations

Shanghai Dongfang Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.